Read
- Kanye West wins over critics with 'daring' new album 'Yeezus'
- Angelina Jolie stunt double sues News Corp over hacking
- Massachusetts police search NFL player's home in homicide probe: report
- Journalist who brought down U.S. general is killed in Los Angeles car crash
- Asian markets tense before Fed; Nikkei outperforms
Sponsored Links
BRIEF-GlaxoSmithKline says Dolutegravir granted FDA priority review
LONDON |
LONDON Feb 15 (Reuters) - GlaxoSmithKline Plc : * Dolutegravir granted FDA priority review * FDA has assigned Dolutegravir a prescription drug user fee act (PDUFA) target
date of 17 August 2013 * Viiv Healthcare announces FDA priority review designation for dolutegravir as
a potential treatment for hiv infection * Source text
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters